Based on the Regenxbio Inc stock forecast from 6 analysts, the average analyst target price for Regenxbio Inc is USD 22.11 over the next 12 months. Regenxbio Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Regenxbio Inc is Bearish, which is based on 1 positive signals and 5 negative signals. At the last closing, Regenxbio Inc’s stock price was USD 5.91. Regenxbio Inc’s stock price has changed by -16.17% over the past week, -6.78% over the past month and -68.91% over the last year.
No recent analyst target price found for Regenxbio Inc
No recent average analyst rating found for Regenxbio Inc
Company Overview Regenxbio Inc
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase III clinical trial for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I, RGX-181 for the treatment of late-infantile neuronal ceroid lipofuscinosis type 2, and RGX-381 for the treatment of the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland. Read Less
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene de...Read More
Frequently Asked Questions About Regenxbio Inc (RGNX) Stock
Based on ratings from 6 analysts Regenxbio Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 11 buy, sell and 1 hold ratings.
Unfortunately we do not have enough data on RGNX's stock to indicate if its a good dividend stock.
Based on targets from 6 analysts, the average taret price for RGNX is USD 22.11 over the next 12 months. The maximum analyst target price is USD 29 while the minimum anlayst target price is USD 14.
RGNX stock's Price/Earning ratio is 12.32.
Our analysis grades RGNX stock's Price / Earning ratio at F. This means that RGNX stock's Price/Earning ratio is above 60% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this RGNX may be a overvalued for its sector.
The last closing price of RGNX's stock was USD 5.91.
The most recent market capitalization for RGNX is USD 0.32B.
Based on targets from 6 analysts, the average taret price for RGNX is projected at USD 22.11 over the next 12 months.
This means that RGNX's stock price may go up by +274.13% over the next 12 months.
We can't find any ETFs which contains Regenxbio Inc's stock.
As per our most recent records Regenxbio Inc has 353 Employees.
Regenxbio Inc's registered address is 9804 Medical Center Drive, Rockville, MD, United States, 20850.
You can get more information about it from Regenxbio Inc's website at https://www.regenxbio.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
What not to like
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Frequently Asked Questions About Regenxbio Inc (RGNX) Stock
Based on ratings from 6 analysts Regenxbio Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 11 buy, sell and 1 hold ratings.
Unfortunately we do not have enough data on RGNX's stock to indicate if its a good dividend stock.
Based on targets from 6 analysts, the average taret price for RGNX is USD 22.11 over the next 12 months. The maximum analyst target price is USD 29 while the minimum anlayst target price is USD 14.
RGNX stock's Price/Earning ratio is 12.32.
Our analysis grades RGNX stock's Price / Earning ratio at F. This means that RGNX stock's Price/Earning ratio is above 60% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this RGNX may be a overvalued for its sector.
The last closing price of RGNX's stock was USD 5.91.
The most recent market capitalization for RGNX is USD 0.32B.
Based on targets from 6 analysts, the average taret price for RGNX is projected at USD 22.11 over the next 12 months.
This means that RGNX's stock price may go up by +274.13% over the next 12 months.
We can't find any ETFs which contains Regenxbio Inc's stock.
As per our most recent records Regenxbio Inc has 353 Employees.
Regenxbio Inc's registered address is 9804 Medical Center Drive, Rockville, MD, United States, 20850.
You can get more information about it from Regenxbio Inc's website at https://www.regenxbio.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for RGNX !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
